![Judith Ng-Cashin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Judith Ng-Cashin
Keine laufenden Positionen mehr
Karriereverlauf von Judith Ng-Cashin
Ehemalige bekannte Positionen von Judith Ng-Cashin
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
EAGLE PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 02.11.2020 | 27.12.2021 |
AOBiome Therapeutics, Inc.
![]() AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von Judith Ng-Cashin
Duke University | Undergraduate Degree |
Rush Medical College | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 4 |
Kanada | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
EAGLE PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
AOBiome Therapeutics, Inc.
![]() AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Judith Ng-Cashin
- Erfahrung